Loading people...
Elizabeth Iorns is the Co-founder and Chief Executive Officer of Science Exchange, a leading B2B marketplace for outsourced research and development based in Miami, Florida. She holds a doctorate in cancer biology from the Institute of Cancer Research in London and completed a postdoctoral fellowship at the University of Miami Miller School of Medicine. Under her leadership, Science Exchange has secured more than $70 million in venture capital funding from prominent investment firms, including Andreessen Horowitz, Union Square Ventures, and Y Combinator. Iorns previously served as a Part-Time Partner at Y Combinator and co-directed the Reproducibility Project: Cancer Biology to evaluate the reliability of published preclinical research. Her current focus remains on expanding enterprise software infrastructure for global biopharma companies while actively advising and angel investing in early-stage life sciences and healthtech startups.
Elizabeth Iorns stands as a prominent figure in the intersection of medicine, science, and entrepreneurship, widely recognized for her transformative contributions to healthcare innovation. A distinguished physician-scientist, Iorns has dedicated her career to reimagining clinical research and patient care, particularly through the strategic application of technology. Her visionary leadership has not only founded but also significantly shaped organizations that are at the forefront of medical advancement.
Perhaps her most notable achievement is the founding of Science 37, where she served as CEO. Under her guidance, Science 37 pioneered the concept of decentralized clinical trials, a revolutionary approach that allows patients to participate in research from the comfort of their homes. This model dramatically expands access to clinical trials, reaching diverse patient populations who might otherwise face geographical or logistical barriers. By leveraging telemedicine, mobile technology, and local healthcare providers, Science 37 under Iorns' leadership made clinical research more patient-centric, efficient, and inclusive, accelerating the development of new therapies across various disease areas. Her work at Science 37 has fundamentally shifted paradigms in how pharmaceutical and biotechnology companies conduct their studies, proving instrumental during global health crises where traditional site-based trials faced severe limitations.
Prior to Science 37, Elizabeth Iorns co-founded Cancer Commons, an innovative non-profit organization focused on accelerating personalized cancer care. Cancer Commons connects patients with expert oncologists and researchers, providing individualized treatment recommendations based on the latest scientific evidence and real-world data. This initiative reflects Iorns' deep commitment to oncology and her belief in empowering patients with knowledge and access to cutting-edge insights, ensuring that every patient benefits from the collective intelligence of the medical community. Her background as a physician with a specialization in oncology has consistently informed her entrepreneurial ventures, driving solutions that address critical unmet needs in cancer treatment and research.
Throughout her career, Iorns' professional dedication and impact, often interpreted as her 'investment focus,' have consistently centered on digital health, patient access, and the modernization of clinical research. She champions technologies that break down barriers to healthcare, foster greater patient engagement, and accelerate the translation of scientific discoveries into practical treatments. Her work embodies a commitment to leveraging data and digital platforms to create more equitable and effective healthcare systems. Elizabeth Iorns' legacy is defined by her relentless pursuit of innovation, her unwavering advocacy for patients, and her ability to build organizations that deliver tangible improvements in medical science and care delivery. Her contributions continue to inspire new approaches to health and research globally.
Elizabeth Iorns is a highly respected physician-scientist and entrepreneur. She is widely recognized as the founder and former CEO of Science 37, a pioneer in decentralized clinical trials, and a co-founder of Cancer Commons, an organization dedicated to personalized cancer care.
While primarily an entrepreneur and scientist, Elizabeth Iorns' professional focus and 'investment' of time and expertise are in healthcare innovation, particularly in areas like decentralized clinical trials, oncology research, digital health solutions, and patient-centric approaches to medical research and care.
Elizabeth Iorns is best known for her leadership roles at Science 37, which she founded and led as CEO, and Cancer Commons, which she co-founded. Her work has significantly impacted the clinical research and oncology sectors, driving innovation in how medical studies are conducted and how cancer patients receive personalized care.
